NCT06584227View on ClinicalTrials.gov

Adebrelimab and Chidamide for Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

July 10, 2025

Study Completion Date

July 10, 2026

Conditions
Pancreatic Cancer, Adult
Interventions
DRUG

Adebrelimab and Chidamide Combined with Gemcitabine and S1

Chidamide：20mg，po，biw，（d8、11、15、18）； Adebrelimab: 1200mg，d8，q3w； Gemcitabine：800-1000mg/m2，bid，d1、d8，q3w； S1：40mg/50mg，bid，d1-14，q3w.

Trial Locations (1)

210000

Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing

All Listed Sponsors
lead

Liu Xiufeng

OTHER

NCT06584227 - Adebrelimab and Chidamide for Pancreatic Cancer | Biotech Hunter | Biotech Hunter